Profile data is unavailable for this security.
About the company
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
- Revenue in USD (TTM)58.47k
- Net income in USD-37.41m
- Incorporated2018
- Employees12.00
- LocationOnconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
- Phone+1 (513) 620-4101
- Fax+1 (845) 818-3588
- Websitehttps://onconetix.gcs-web.com/
More ▼
Mergers & acquisitions
| Acquired company | ONCO:NAQ since announced | Transaction value |
|---|---|---|
| ProteoMediX Ltd | -24.21% | -- |
| Wraser LLC | -76.97% | 3.50m |
Data delayed at least 15 minutes, as of May 24 2024 20:59 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sentient Brands Holdings Inc | 0.00 | -818.63k | 3.73m | 2.00 | -- | -- | -- | -- | -0.0145 | -0.0145 | 0.00 | -0.036 | 0.00 | 0.0188 | -- | 0.00 | -317.87 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0354 | -2.27 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| 60 Degrees Pharmaceuticals Inc | 378.20k | -1.07m | 3.82m | 2.00 | -- | -- | -- | 10.11 | -0.1563 | -0.1563 | 0.0564 | 0.6121 | 0.0474 | 0.8827 | 1.90 | 126,066.70 | -9.87 | -- | -- | -- | -23.45 | -- | -208.43 | -- | 6.77 | -- | 0.0217 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
| Gold River Productions Inc. | -100.00bn | -100.00bn | 3.99m | 1.00k | -- | 6.14 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
| Altamira Therapeutics Ltd | 0.00 | -7.95m | 3.99m | 10.00 | -- | 0.3726 | -- | -- | -16.18 | -8.61 | 0.00 | 4.78 | 0.00 | 34.05 | 32.30 | 0.00 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -- | -- | 1.38 | -4.37 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
| TRACON Pharmaceuticals Inc | 12.15m | 1.75m | 3.99m | 17.00 | 2.29 | -- | 2.27 | 0.3287 | 0.6509 | 0.6509 | 6.27 | -0.6618 | 1.37 | -- | -- | 714,411.80 | 19.78 | -79.42 | -- | -177.85 | -- | -- | 14.39 | -813.81 | -- | -0.4613 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
| Onconetix Inc | 58.47k | -37.41m | 4.06m | 12.00 | -- | -- | -- | 69.46 | -2.09 | -2.09 | 0.0034 | 2.63 | 0.001 | -- | 0.6301 | 4,872.50 | -65.73 | -- | -87.29 | -- | -1,927.76 | -- | -63,981.00 | -- | 0.3185 | -19.88 | 0.1292 | -- | -- | -- | -176.78 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -24.99m | 4.12m | 31.00 | -- | -- | -- | -- | -29.21 | -29.21 | 0.00 | -3.81 | 0.00 | -- | -- | 0.00 | -171.18 | -161.49 | -- | -213.01 | -- | -- | -- | -- | -- | -15.69 | 1.87 | -- | -- | -- | -35.90 | -- | 177.42 | -- |
| Alzamend Neuro Inc | 0.00 | -15.16m | 4.13m | 4.00 | -- | -- | -- | -- | -2.32 | -2.32 | 0.00 | -0.4146 | 0.00 | -- | -- | 0.00 | -265.85 | -- | -496.81 | -- | -- | -- | -- | -- | -- | -1,736.10 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -9.38m | 4.17m | 8.00 | -- | 0.6268 | -- | -- | -3.71 | -3.71 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Petros Pharmaceuticals Inc | 4.69m | -20.46m | 4.27m | 21.00 | -- | 0.429 | -- | 0.9099 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Regen BioPharma Inc | 236.58k | -851.69k | 4.32m | 1.00 | -- | -- | -- | 18.26 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Ensysce Biosciences Inc | 1.75m | -11.55m | 4.32m | 7.00 | -- | 1.11 | -- | 2.48 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Neximmune Inc | 0.00 | -32.34m | 4.36m | 6.00 | -- | 0.9665 | -- | -- | -30.86 | -30.86 | 0.00 | 3.29 | 0.00 | -- | -- | 0.00 | -125.24 | -115.07 | -178.52 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| Geovax Labs Inc | 0.00 | -27.78m | 4.40m | 17.00 | -- | 74.00 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Onconetix Inc's reporting currency: US Dollar USD
11.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| American Money Management Corp.as of 31 Mar 2024 | 1.44m | 6.45% |
| Cetera Advisor Networks LLCas of 31 Mar 2024 | 320.00k | 1.43% |
| Cetera Investment Advisers LLCas of 31 Mar 2024 | 320.00k | 1.43% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 125.00k | 0.56% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 113.43k | 0.51% |
| Fifth Third Bank, NA (Investment Management)as of 31 Mar 2024 | 96.20k | 0.43% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 73.51k | 0.33% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 53.56k | 0.24% |
| Geode Capital Management LLCas of 31 Mar 2024 | 53.11k | 0.24% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 38.29k | 0.17% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
